India's trade nears $1.84 trillion as NITI Aayog's Trade Watch spotlights pharma exports

NITI Aayog's eighth Trade Watch Quarterly reports India's merchandise-and-services trade grew 5.4% to $1.84 trillion in 2025-26, with a thematic deep-dive on pharmaceuticals — a sector central to India's 'pharmacy of the world' role.

What happened

• NITI Aayog Vice-Chairman Shri Ashok Kumar Lahiri released the eighth edition of the 'Trade Watch Quarterly' for Q4 of FY2025-26 (January-March 2026) on 23 June 2026.
• The publication provides a comprehensive assessment of global and domestic trade trends, noting global trade's resilience despite macroeconomic and geopolitical uncertainties.
• India's trade remained broadly stable, with total merchandise and services trade expanding 5.4% year-on-year to reach $1.84 trillion during April-March FY2025-26.
• The edition's thematic focus is the pharmaceutical sector — one of India's most globally competitive industries and a major provider of generic medicines, vaccines and essential therapeutics.
• The study maps global demand against India's export profile to identify untapped opportunities and scope for higher value addition and market diversification.

For Prelims

• Trade Watch Quarterly: A NITI Aayog publication tracking India's and global trade trends, with a thematic sectoral focus each edition (this 8th edition: pharmaceuticals).
• NITI Aayog: The National Institution for Transforming India — the government's apex public-policy think tank (replaced the Planning Commission in 2015); chaired by the PM, with a Vice-Chairman and CEO.
• India's pharma sector: India is the 'pharmacy of the world' — the largest supplier of generic medicines by volume and a major vaccine producer (e.g. via the Serum Institute); strong in formulations but import-dependent for some APIs (bulk drugs).
• Trade balance terms: 'Merchandise + services trade' is gross trade (exports + imports); India runs a merchandise trade deficit but a services trade surplus (IT, etc.).
• PLI for pharma/APIs: Production-Linked Incentive schemes (and bulk-drug parks) aim to cut API import dependence and move up the pharma value chain.
• Export diversification: India seeks new markets and higher value addition (biosimilars, complex generics) to deepen its pharma export competitiveness.
• Don't confuse: $1.84 trillion is total two-way trade (merchandise + services), not just exports; the 5.4% is year-on-year growth, and the report is a NITI Aayog publication, not official trade data (DGCI&S/RBI).

For Mains

Syllabus: GS3.1 · GS2.18 · Linkage L2